AIC
JNCE

Ameritas Investment Company’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Ameritas Investment Company’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-100
Closed – – 1707
2020
Q1 		$0 Buy
+100
New +$576 ﹤0.01% 1856

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Ameritas Investment Company's JNCE Position: Q2 2020 in Review

Ameritas Investment Company sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2020, closing a stake of 100 shares.

Ameritas Investment Company first reported a position in JNCE in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 90 funds tracked by Wall St. Rank hold JNCE as of Q2 2020.

  • Ameritas Investment Company reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Ameritas Investment Company sold 100 Jounce Therapeutics, Inc. Common Stock shares in Q2 2020.
  • Ameritas Investment Company first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Ameritas Investment Company's Jounce Therapeutics, Inc. Common Stock position peaked at $0 in Q1 2020.
  • 90 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Ameritas Investment Company's 13F filing for Q2 2020, filed 14 Aug 2020.